BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 23922757)

  • 1. Comparison between internalizing anti-HER2 mAbs and non-internalizing anti-CEA mAbs in alpha-radioimmunotherapy of small volume peritoneal carcinomatosis using 212Pb.
    Boudousq V; Bobyk L; Busson M; Garambois V; Jarlier M; Charalambatou P; Pèlegrin A; Paillas S; Chouin N; Quenet F; Maquaire P; Torgue J; Navarro-Teulon I; Pouget JP
    PLoS One; 2013; 8(7):e69613. PubMed ID: 23922757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Noninternalizing monoclonal antibodies are suitable candidates for 125I radioimmunotherapy of small-volume peritoneal carcinomatosis.
    Santoro L; Boutaleb S; Garambois V; Bascoul-Mollevi C; Boudousq V; Kotzki PO; Pèlegrin M; Navarro-Teulon I; Pèlegrin A; Pouget JP
    J Nucl Med; 2009 Dec; 50(12):2033-41. PubMed ID: 19910417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brief intraperitoneal radioimmunotherapy of small peritoneal carcinomatosis using high activities of noninternalizing 125I-labeled monoclonal antibodies.
    Boudousq V; Ricaud S; Garambois V; Bascoul-Mollevi C; Boutaleb S; Busson M; Quenet F; Colombo PE; Bardiès M; Kotzki PO; Navarro-Teulon I; Pèlegrin A; Pouget JP
    J Nucl Med; 2010 Nov; 51(11):1748-55. PubMed ID: 20956481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pretargeted radioimmunotherapy and SPECT imaging of peritoneal carcinomatosis using bioorthogonal click chemistry: probe selection and first proof-of-concept.
    Rondon A; Schmitt S; Briat A; Ty N; Maigne L; Quintana M; Membreno R; Zeglis BM; Navarro-Teulon I; Pouget JP; Chezal JM; Miot-Noirault E; Moreau E; Degoul F
    Theranostics; 2019; 9(22):6706-6718. PubMed ID: 31588245
    [No Abstract]   [Full Text] [Related]  

  • 5. Potentiation of high-LET radiation by gemcitabine: targeting HER2 with trastuzumab to treat disseminated peritoneal disease.
    Milenic DE; Garmestani K; Brady ED; Albert PS; Abdulla A; Flynn J; Brechbiel MW
    Clin Cancer Res; 2007 Mar; 13(6):1926-35. PubMed ID: 17363549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Theranostic pretargeted radioimmunotherapy of internalizing solid tumor antigens in human tumor xenografts in mice: Curative treatment of HER2-positive breast carcinoma.
    Cheal SM; Xu H; Guo HF; Patel M; Punzalan B; Fung EK; Lee SG; Bell M; Singh M; Jungbluth AA; Zanzonico PB; Piersigilli A; Larson SM; Cheung NV
    Theranostics; 2018; 8(18):5106-5125. PubMed ID: 30429889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined radioimmunotherapy and chemotherapy of breast tumors with Y-90-labeled anti-Her2 and anti-CEA antibodies with taxol.
    Crow DM; Williams L; Colcher D; Wong JY; Raubitschek A; Shively JE
    Bioconjug Chem; 2005; 16(5):1117-25. PubMed ID: 16173788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alpha-particle radioimmunotherapy of disseminated peritoneal disease using a (212)Pb-labeled radioimmunoconjugate targeting HER2.
    Milenic DE; Garmestani K; Brady ED; Albert PS; Ma D; Abdulla A; Brechbiel MW
    Cancer Biother Radiopharm; 2005 Oct; 20(5):557-68. PubMed ID: 16248771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic efficacy and tumor dose estimations in radioimmunotherapy of intraperitoneally growing OVCAR-3 cells in nude mice with (211)At-labeled monoclonal antibody MX35.
    Elgqvist J; Andersson H; Bäck T; Hultborn R; Jensen H; Karlsson B; Lindegren S; Palm S; Warnhammar E; Jacobsson L
    J Nucl Med; 2005 Nov; 46(11):1907-15. PubMed ID: 16269606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radioimmunotherapy targeting of HER2/neu oncoprotein on ovarian tumor using lead-212-DOTA-AE1.
    Horak E; Hartmann F; Garmestani K; Wu C; Brechbiel M; Gansow OA; Landolfi NF; Waldmann TA
    J Nucl Med; 1997 Dec; 38(12):1944-50. PubMed ID: 9430475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
    Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM
    J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose escalation and dosimetry of first-in-human α radioimmunotherapy with 212Pb-TCMC-trastuzumab.
    Meredith R; Torgue J; Shen S; Fisher DR; Banaga E; Bunch P; Morgan D; Fan J; Straughn JM
    J Nucl Med; 2014 Oct; 55(10):1636-42. PubMed ID: 25157044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of HER2-Targeted Intraperitoneal
    Chung SK; Vargas DB; Chandler CS; Katugampola S; Veach DR; McDevitt MR; Seo SH; Vaughn BA; Rinne SS; Punzalan B; Patel M; Xu H; Guo HF; Zanzonico PB; Monette S; Yang G; Ouerfelli O; Nash GM; Cercek A; Fung EK; Howell RW; Larson SM; Cheal SM; Cheung NV
    J Nucl Med; 2023 Sep; 64(9):1439-1445. PubMed ID: 37348919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and normal tissue toxicity of Auger electron (AE) radioimmunotherapy (RIT) with [
    Chan C; Fonge H; Lam K; Reilly RM
    Nucl Med Biol; 2020; 80-81():37-44. PubMed ID: 31706737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic advantages of Auger electron- over beta-emitting radiometals or radioiodine when conjugated to internalizing antibodies.
    Behr TM; Béhé M; Löhr M; Sgouros G; Angerstein C; Wehrmann E; Nebendahl K; Becker W
    Eur J Nucl Med; 2000 Jul; 27(7):753-65. PubMed ID: 10952487
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Quelven I; Monteil J; Sage M; Saidi A; Mounier J; Bayout A; Garrier J; Cogne M; Durand-Panteix S
    J Nucl Med; 2020 Jul; 61(7):1058-1065. PubMed ID: 31862796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiolabeled Antibodies Against Müllerian-Inhibiting Substance Receptor, Type II: New Tools for a Theranostic Approach in Ovarian Cancer.
    Deshayes E; Ladjohounlou R; Le Fur P; Pichard A; Lozza C; Boudousq V; Sevestre S; Jarlier M; Kashani R; Koch J; Sosabowski J; Foster J; Chouin N; Bruchertseifer F; Morgenstern A; Kotzki PO; Navarro-Teulon I; Pouget JP
    J Nucl Med; 2018 Aug; 59(8):1234-1242. PubMed ID: 29674421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radioimmunotherapy is an effective adjuvant treatment after cytoreductive surgery of experimental colonic peritoneal carcinomatosis.
    Koppe MJ; Hendriks T; Boerman OC; Oyen WJ; Bleichrodt RP
    J Nucl Med; 2006 Nov; 47(11):1867-74. PubMed ID: 17079821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radioimmunotherapy of human pancreatic cancer xenografts in NOD-scid mice with [
    Boyle AJ; Cao PJ; Cai Z; Chan C; Hedley DW; Reilly RM
    Nucl Med Biol; 2020; 84-85():46-54. PubMed ID: 32062317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted alpha therapy with 227Th-trastuzumab of intraperitoneal ovarian cancer in nude mice.
    Heyerdahl H; Abbas N; Sponheim K; Mollatt C; Bruland Ø; Dahle J
    Curr Radiopharm; 2013 Jun; 6(2):106-16. PubMed ID: 23551111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.